Teva Pharmaceutical Industries Limited

Taro Pharmaceutical Industries Limited

Rachel Cohen

Anton Frenkel

Muhammad Safadi

Marina Zholkovsky

Ramy Lidor-Hadas

Eliezer Bahar

Daniella Licht

Danit Licht

Michal Keisar

Michael M Friedman

Avraham Yacobi

The subject invention provides R(+)-N-formyl-propargyl-aminoindan and a composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-formyl-propargyl-aminoindan.

R(+)-N-formyl-propargyl-aminoindan

The subject invention provides R(+)-N-methyl-propargyl-aminoindan or a pharmaceutically acceptable salt thereof and a composition containing R(+)-N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-methyl-propargyl-aminoindan or a salt thereof.

R(+)-N-methyl-propargyl-aminoindan

Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties.

Delayed release rasagiline citrate formulation

A topical sustained release delivery system for delivery of antifungal agents to the finger or toenails achieving high penetration through the nails by combining the antifingal agent with a keratolytic agent and a humectant. The pharmaceutical sustained release topical preparation is provided in a varnish or spray form for treating the nail and surrounding tissues, where the active ingredient is an antifungal agent, a keratolytic agent, or preferably a combination of an antifuingal and a keratolytic agent. The composition may further comprise an antibacterial, an antiviral, an antipsoriatic agents, or combinations thereof.

Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections

Growing community of inventors

Hadera, Israel

Rachel Cohen